Featured
HUNTSVILLE, Ala. -- Sleeping, eating, working; humans, as well as many other living organisms, have circadian patterns, regularly occurring, 24-hour rhythms, that are part of normal function. Dysfunctions in regular patterns – such as insomnia and unexplained fluctuations in appetite, body temperature and/or hormones — are symptoms shared by many patients with depression. Researchers at the HudsonAlpha Institute for Biotechnology, with scientists at the University of Michigan, the University of California at Irvine, Stanford University and Weill Cornell Medical College, collaborated in a study where they found the first direct evidence connecting cellular level activity in the brains of patients with depression to out-of-step circadian rhythms. These groups have been part of the Pritzker Neuropsychiatric Disorders Research Consortium for the past decade.
HudsonAlpha's educational outreach team received a big boost from BBVA Compass Bank when the local financial institution donated almost $6,000 toward the Science for Me Too! program. iCell now available on Windows 8 platform
HUNTSVILLE, Ala. – HudsonAlpha’s iCell is now fully available on the Windows 8 platform, potentially reaching an audience of more than 4 million Windows 8 users worldwide. The new Microsoft system features easier-to-open apps for tablets and PCs, making iCell easier to access on Windows 8 devices.
“It simplifies the process of being able to use the iCell application,” said Adam Hott, Ed.D., coordinator of educational outreach. “This makes iCell more accessible and puts it in the hands of users more efficiently.”
HUNTSVILLE, Ala. -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer. The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, Inc. Premal Thaker, M.D., M.S., of Washington University School of Medicine, is the Study Chair for the trial.
Huntsville, Ala. – Joseph M. Cosumano joins CFD Research Corporation (CFDRC) as president, effective Feb. 1, 2013. Cosumano’s military and civilian experience in key modernization efforts make him a perfect fit to lead CFDRC as it continues to make significant discoveries and applications. 
Serina Therapeutics, Inc. has developed a proprietary, patented polymer technology for drug development and announced an agreement with AstraZeneca to develop the polyoxazoline (POZ) polymer therapeutic with an AstraZeneca proprietary compound. The nature of the POZ therapeutic and the terms of the agreement were not immediately disclosed. Jeremy Schmutz receives cotton biotechnology award
News Outlet:
PR Newswire
Date published:
January 16, 2013 
NEW YORK, Jan. 17, 2013 -- As part of the recent Plant and Animal Genomic Conference held in San Diego, Calif., Dr. Don Jones of Cotton Incorporated presented the 2012 Cotton Biotechnology Award to five outstanding researchers that were instrumental in mapping the cotton genome. The diverse and talented team, composed of Dr. Andrew Paterson, Dr. Jonathan Wendel, Mr. Jeremy Schmutz, Dr. Dan Peterson and Dr. Dan Rokhsar, led the collaborative international effort to complete the first "gold standard" Gossypium genome sequence. 
HUNTSVILLE, Alabama - The Rocket City's battle against bulge is getting serious. On Tuesday, Mayor Tommy Battle announced an expanded 